Quick Answer
Olema Pharmaceuticals, Inc. reported Net Income of -$162.45 million for fiscal year 2025.
Olema Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$162.45M -25.5% |
-$129.47M -34.0% |
-$96.66M +7.8% |
-$104.79M -47.4% |
-$71.10M -221.4% |
-$22.12M -412.5% |
| Diluted EPS | -$1.87 +15.0% |
-$2.20 -2.8% |
-$2.14 +18.3% |
-$2.62 -45.6% |
-$1.80 +47.4% |
-$3.42 -106.0% |
| Total Assets | $533.43M +18.3% |
$450.98M +62.8% |
$276.94M +28.4% |
$215.65M -27.1% |
$295.94M -13.6% |
$342.72M |
| Cash and Equivalents | $48.30M -65.4% |
$139.48M +103.5% |
$68.54M +189.2% |
$23.70M +71.6% |
$13.81M -95.9% |
$338.55M |
| Stockholders Equity | $478.56M +17.0% |
$408.96M +61.1% |
$253.90M +28.5% |
$197.55M -30.6% |
$284.57M -15.8% |
$338.14M +3291.8% |
| R&D Expense | $157.70M +26.6% |
$124.52M +44.6% |
$86.14M +4.7% |
$82.27M +61.0% |
$51.10M +272.9% |
$13.70M +249.6% |
| Operating Income | -$178.70M -25.6% |
-$142.26M -35.5% |
-$104.96M +1.9% |
-$106.99M -49.7% |
-$71.49M -232.1% |
-$21.53M -398.0% |
| Shares Outstanding | 81.38M +9.5% |
74.31M +35.1% |
54.99M +36.5% |
40.29M +1.2% |
39.80M +1.2% |
39.31M |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$42.22M | -22.2% | +3.6% |
| Diluted EPS | September 30, 2025 | -$0.49 | +18.3% | +3.9% |
| Total Assets | September 30, 2025 | $352.45M | +53.1% | -7.7% |
| Cash and Equivalents | September 30, 2025 | $35.26M | -1.7% | -32.8% |
| Stockholders Equity | September 30, 2025 | $307.49M | +54.6% | -10.9% |
| R&D Expense | September 30, 2025 | $39.95M | +20.2% | -9.0% |
| Operating Income | September 30, 2025 | -$45.88M | -21.9% | +4.2% |
| Shares Outstanding | September 30, 2025 | 68.65M | +19.8% | +0.0% |
- Olema Pharmaceuticals, Inc. reported Net Income of -$162.45 million for fiscal year 2025.
- Olema Pharmaceuticals, Inc. showed a decrease of -25.5% in Net Income compared to the prior fiscal year.
- Olema Pharmaceuticals, Inc. reported Diluted EPS of $1.87 per share (loss) for fiscal year 2025.
- Olema Pharmaceuticals, Inc. showed an increase of +15.0% in Diluted EPS compared to the prior fiscal year.
- Olema Pharmaceuticals, Inc. reported Total Assets of $533.43 million for fiscal year 2025.
- Olema Pharmaceuticals, Inc. showed an increase of +18.3% in Total Assets compared to the prior fiscal year.
- Olema Pharmaceuticals, Inc. reported Cash and Equivalents of $48.30 million for fiscal year 2025.
- Olema Pharmaceuticals, Inc. showed a decrease of -65.4% in Cash and Equivalents compared to the prior fiscal year.
- Olema Pharmaceuticals, Inc. reported Stockholders Equity of $478.56 million for fiscal year 2025.
- Olema Pharmaceuticals, Inc. showed an increase of +17.0% in Stockholders Equity compared to the prior fiscal year.
- Olema Pharmaceuticals, Inc. reported R&D Expense of $157.70 million for fiscal year 2025.
- Olema Pharmaceuticals, Inc. showed an increase of +26.6% in R&D Expense compared to the prior fiscal year.
- Olema Pharmaceuticals, Inc. reported Operating Income of -$178.70 million for fiscal year 2025.
- Olema Pharmaceuticals, Inc. showed a decrease of -25.6% in Operating Income compared to the prior fiscal year.
- Olema Pharmaceuticals, Inc. reported Shares Outstanding of 81.38 million shares for fiscal year 2025.
- Olema Pharmaceuticals, Inc. showed an increase of +9.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: